 |
|
|
| |
Daclatasvir Plus Sofosbuvir Plus Ribavirin for
12 or 16 Weeks in Treatment-Experienced Patients with
HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Hézode C,1 Dore GJ,2 Pianko S,3 Pol S,4 Stuart K,5 Thompson A,4
Tse E,6 Bhore R,7 Jimenez-Exposito MJ7
1Hépato-gastro-entérologie, CHU Henri-Mondor, Créteil, France; 2St. Vincent's Hospital and Kirby Institute, Sydney, Australia; 3Monash Medical Centre, Clayton, Australia; 4Hôpital Cochin, Paris, France; 5Gallipoli Medical Research Foundation, Greenslopes, Australia; 6Royal Adelaide Hospital, Adelaide, Australia; 7Bristol-Myers Squibb Research & Development, Princeton, NJ, USA
|
| |
|
|
|
|
|
